PTEN and TRAIL genes loaded zein nanoparticles as potential therapy for hepatocellular carcinoma

References

• Lafaro KJ, Demirjian AN, Pawlik TM. Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am 2015;24:1–17.
   PubMed Web of Science ®Google Scholar
• Natsume A, Yoshida J. Gene therapy for high-grade glioma: current approaches and future directions. Cell Adh Migr 2008;2:186–91.
   PubMed Web of Science ®Google Scholar
• Jia LT, Chen SY, Yang AG. Cancer gene therapy targeting cellular apoptosis machinery. Cancer Treat Rev 2012;38:868–76.
   PubMed Web of Science ®Google Scholar
• Mali S. Delivery systems for gene therapy. Indian J Hum Genet 2013;19:3–8.
   PubMedGoogle Scholar
• Mishra B, Patel BB, Tiwari S. Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery. Nanomedicine 2010;6:9–24.
   PubMed Web of Science ®Google Scholar
• Ditto AJ, Shah PN, Yun YH. Non-viral gene delivery using nanoparticles. Expert Opin Drug Deliv 2009;6:1149–60.
   PubMed Web of Science ®Google Scholar
• Koo OM, Rubinstein I, Onyuksel H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomedicine 2005;1:193–212.
   PubMed Web of Science ®Google Scholar
• Lohcharoenkal W, Wang L, Chen YC, Rojanasakul Y. Protein nanoparticles as drug delivery carriers for cancer therapy. BioMed Res Int 2014;2014:180549–60.
   PubMed Web of Science ®Google Scholar
• Shukla R, Cheryan M. Zein: the industrial protein from corn. Ind Crops Prod 2001;13:171–92.
   Web of Science ®Google Scholar
• Regier MC, Taylor JD, Borcyk T, Pannier AK. Fabrication and characterization of DNA-loaded zein nanospheres. J Nanobiotechnol 2012;10:44.
   PubMed Web of Science ®Google Scholar
• Deo N, Jockusch S, Turro NJ, Somasundaran P. Surfactant interactions with zein protein. Langmuir 2003;19:5083–8.
   Web of Science ®Google Scholar
• Sun QS, Dong J, Lin Zx, et al. Comparison of cytocompatibility of zein film with other biomaterials and its degradability in vitro. Biopolymers 2005;78:268–74.
   PubMed Web of Science ®Google Scholar
• Wang HJ, Lin ZX, Liu XM, et al. Heparin-loaded zein microsphere film and hemocompatibility. J Control Release 2005;105:120–31.
   PubMed Web of Science ®Google Scholar
• Lai LF, Guo HX. Preparation of new 5-fluorouracil-loaded zein nanoparticles for liver targeting. Int J Pharm 2011;404:317–23.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Cui L, Li F, et al. Design, fabrication and biomedical applications of zein-based nano/micro-carrier systems. Int J Pharm 2016;513:191–210.
   PubMed Web of Science ®Google Scholar
• Rasekh M, Young C, Roldo M, et al. Hollow-layered nanoparticles for therapeutic delivery of peptide prepared using electrospraying. J Mater Sci Mater Med 2015;26:256.
   PubMed Web of Science ®Google Scholar
• Ekemen Z, Chang H, Ahmad Z, et al. Fabrication of biomaterials via controlled protein bubble generation and manipulation. Biomacromolecules 2011;12:4291–300.
   PubMed Web of Science ®Google Scholar
• Mehta P, Haj-Ahmad R, Rasekh M, et al. Pharmaceutical and biomaterial engineering via electrohydrodynamic atomization technologies. Drug Discov Today 2017;22:157–65.
   PubMed Web of Science ®Google Scholar
• Rasekh M, Karavasili C, Soong YL, et al. Electrospun PVP-indomethacin constituents for transdermal dressings and drug delivery devices. Int J Pharm 2014;473:95–104.
   PubMed Web of Science ®Google Scholar
• Podaralla S, Perumal O. Influence of formulation factors on the preparation of zein nanoparticle. AAPS PharmSciTech 2012;13:919–27.
   PubMed Web of Science ®Google Scholar
• Fernández M, Semela D, Bruix J, et al. Angiogenesis in liver disease. J Hepatol 2009;50:604–20.
   PubMed Web of Science ®Google Scholar
• Lebedeva IV, Su ZZ, Sarkar D, Fisher PB. Restoring apoptosis as a strategy for cancer gene therapy: focus on p53 and mda-7. Semin Cancer Biol 2003;13:169–78.
   PubMed Web of Science ®Google Scholar
• Griffith TS, Stokes B, Kucaba TA, et al. TRAIL gene therapy: from preclinical development to clinical application. Curr Gene Ther 2009;9:9–19.
   PubMed Web of Science ®Google Scholar
• Griffith TS, Anderson RD, Davidson BL. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol 2000;165:2886–94.
   PubMed Web of Science ®Google Scholar
• Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943–7.
   PubMed Web of Science ®Google Scholar
• Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997;15:356–62.
   PubMed Web of Science ®Google Scholar
• Ruan ZP, Xu R, Lv Y, et al. PTEN enhances the sensitivity of human hepatocellular carcinoma cells to sorafenib. Oncol Res 2012;20:113–21.
   PubMed Web of Science ®Google Scholar
• Li D, Zhang Y, Xie Y, et al. Enhanced tumor suppression by adenoviral PTEN gene therapy combined with cisplatin chemotherapy in small-cell lung cancer. Cancer Gene Ther 2013;20:251–9.
   PubMed Web of Science ®Google Scholar
• Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nature Rev 2006;6:184–92.
   Web of Science ®Google Scholar
• Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell 2008;133:403–14.
   PubMed Web of Science ®Google Scholar
• Kagawa S, He C, Gu J, et al. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res 2001;61:330–8.
   Web of Science ®Google Scholar
• Liu F, Wagner S, Campbell RB, et al. PTEN enters the nucleus by diffusion. J Cell Biochem 2005;96:221–34.
   PubMed Web of Science ®Google Scholar
• Feliciello I, Chinali G. A modified alkaline lysis method for the preparation of highly purified plasmid DNA from Escherichia coli. Anal Biochem 1993;212:394–401.
   PubMed Web of Science ®Google Scholar
• Hu K, McClements DJ. Fabrication of surfactant-stabilized zein nanoparticles: a pH modulated antisolvent precipitation method. Food Res Int 2014;64:329–35.
   PubMed Web of Science ®Google Scholar
• Wilson K. Preparation of genomic DNA from bacteria. In: Ausubel M, ed. Current protocols in molecular biology. 2001;Chapter 2:Unit 2.4.
   Google Scholar
• Repetto G, del Peso A, Zurita JL. Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat Protoc 2008;3:1125–31.
   PubMed Web of Science ®Google Scholar
• Abdel aziz MT, El Asmar MF, Atta HM, et al. Efficacy of mesenchymal stem cells in suppression of hepatocarcinorigenesis in rats: possible role of Wnt signaling. J Exp Clin Cancer Res 2011;30:49–60.
   PubMed Web of Science ®Google Scholar
• Sharma B, Ma W, Adjei IM, et al. Nanoparticle-mediated p53 gene therapy for tumor inhibition. Drug Deliv Transl Res 2011;1:43–52.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Oyamada M, Fujimoto Y, et al. Elevation of serum alpha-fetoprotein and proliferation of oval cells in the livers of LEC rats. Jpn J Cancer Res 1988;79:821–7.
   PubMedGoogle Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (San Diego, Calif.) 2001;25:402–8.
   PubMed Web of Science ®Google Scholar
• Bungenberg de Jong HB, Kruyt HR. Coacervation (Partial Miscibility in Colloid Systems). Proc Sect Sci 1929;32:849–56.
   Google Scholar
• Hurtado-López P, Murdan S. Formulation and characterisation of zein microspheres as delivery vehicles. J Drug Deliv Sci Technol 2005;15:267–72.
   Web of Science ®Google Scholar
• Tian T, Nan KJ, Guo H, et al. PTEN inhibits the migration and invasion of HepG2 cells by coordinately decreasing MMP expression via the PI3K/Akt pathway. Oncol Rep 2010a;23:1593–600.
   PubMed Web of Science ®Google Scholar
• Tian T, Nan KJ, Wang SH, et al. PTEN regulates angiogenesis and VEGF expression through phosphatase-dependent and -independent mechanisms in HepG2 cells. Carcinogenesis 2010b;31:1211–9.
   PubMed Web of Science ®Google Scholar
• Sun J, Luo H, Nie W, et al. Protective effect of RIP and c-FLIP in preventing liver cancer cell apoptosis induced by TRAIL. Int J Clin Exp Pathol 2015;8:6519–25.
   PubMed Web of Science ®Google Scholar
• Sun XY, Hong J, Qin K, et al. MSC(TRAIL)-mediated HepG2 cell death in direct and indirect co-cultures. Anticancer Res 2011;31:3705–12.
   PubMed Web of Science ®Google Scholar
• Qi R, Cai Y, Lin ZX, Gu JF. Specific antitumor effect of adeno-associated virus vector carrying TRAIL gene under the control of hTERT promoter. Ai Zheng 2008;27:1026–33.
   PubMedGoogle Scholar
• Goldfarb S, Pugh TD, Koscluk S, Chover J. Kinetics of diethylnitrosamine hepatocarcinogenesis in the infant mouse. Cancer Res 1985;45:909–12.
   PubMed Web of Science ®Google Scholar
• Uehara T, Ainslie GR, Kutanzi K, et al. Molecular mechanisms of fibrosis-associated promotion of liver carcinogenesis. Toxicol Sci 2013;132:53–63.
   PubMed Web of Science ®Google Scholar
• Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol 2013;47:S2–S6.
   PubMed Web of Science ®Google Scholar
• Schmitt CA, Rosenthal CT, Lowe SW. Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med 2000;6:1029–35.
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307–10.
   PubMed Web of Science ®Google Scholar
• Van Gijssel HE, Maassen CB, Mulder GJ, Meerman JH. p53 protein expression by hepatocarcinogens in the rat liver and its potential role in mitoinhibition of normal hepatocytes as a mechanism of hepatic tumour promotion. Carcinogenesis 1997;18:1027–33.
   PubMed Web of Science ®Google Scholar
• Zhao J, Lu Y, Shen HM. Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells. Cancer Lett 2012;314:8–23.
   PubMed Web of Science ®Google Scholar
• Fischer U, Schulze-Osthoff K. Apoptosis-based therapies and drug targets. Cell Death and Differentiation 2005;12:942–61.
   PubMed Web of Science ®Google Scholar
• Nakanishi A, Kitagishi Y, Ogura Y, Matsuda S. The tumor suppressor PTEN interacts with p53 in hereditary cancer (Review). Int J Oncol 2014;44:1813–9.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocrine Rev 1997;18:4–25.
   PubMed Web of Science ®Google Scholar
• Ma J, Sawai H, Ochi N, et al. PTEN regulates angiogenesis through PI3K/Akt/VEGF signaling pathway in human pancreatic cancer cells. Mol Cell Biochem 2009;331:161–71.
   PubMed Web of Science ®Google Scholar
• Li N, Qin J, Lan L, et al. PTEN inhibits macrophage polarization from M1 to M2 through CCL2 and VEGF-A reduction and NHERF-1 synergism. Cancer Biol Ther 2015;16:297–306.
   PubMed Web of Science ®Google Scholar
• Rodriguez S, Huynh-Do U. The role of PTEN in tumor angiogenesis St. J Oncol 2011;2012:1–11.
   Google Scholar
• Ye Z, Huang Y, Li LF, et al. Argonaute 2 promotes angiogenesis via the PTEN/VEGF signaling pathway in human hepatocellular carcinoma. Nature 2015;36:1237–45.
   Google Scholar
• Secchiero P, Gonelli A, Carnevale E, et al. Evidence for a proangiogenic activity of TNF-related apoptosis-inducing ligand. Neoplasia 2004;6:364–73.
   PubMed Web of Science ®Google Scholar
• Bartolo DBA, Cartland SP, Prado-Lourenco L, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) promotes angiogenesis and ischemia-induced neovascularization via NADPH oxidase 4 (NOX4) and nitric oxide-dependent mechanisms. JAHA 2015;4:e002527.
   Google Scholar
• Ishimura N, Isomoto H, Bronk SF, et al. Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol 2006;290:G129–36.
   PubMedGoogle Scholar
• Trauzold A, Röder C, Sipos B, et al. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 2006;25:7434–9.
   PubMed Web of Science ®Google Scholar
• Wang S, Ren W, Liu J, et al. TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in-vivo. Clin Cancer Res 2010;16:2591–604.
   PubMed Web of Science ®Google Scholar
• Na HJ, Hwang JY, Lee KS, et al. TRAIL negatively regulates VEGF-induced angiogenesis via caspase-8-mediated enzymatic and non-enzymatic functions. Angiogenesis 2014;17:179–94.
   PubMed Web of Science ®Google Scholar
• Chen PL, Easton AS. Evidence that tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits angiogenesis by inducing vascular endothelial cell apoptosis. Biochem Biophys Res Commun 2010;391:936–41.
   PubMed Web of Science ®Google Scholar
• Cantarella G, Risuglia N, Dell'eva R, et al. TRAIL inhibits angiogenesis stimulated by VEGF expression in human glioblastoma cells. Br J Cancer 2006;94:1428–35.
   PubMed Web of Science ®Google Scholar
• Turck J, Pollock AS, Lee LK, et al. Matrix metalloproteinase 2 (gelatinase A) regulates glomerular mesangial cell proliferation and differentiation. J Biol Chem 1996;271:15074–83.
   PubMed Web of Science ®Google Scholar
• Zheng W, Zhang LJ, Shi MN, et al. Expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 in hepatic stellate cells during rat hepatic fibrosis and its intervention by IL-10. World J Gastroenterol 2005;11:1753.
   PubMed Web of Science ®Google Scholar
• Siddiqui IA, Malik A, Adhami VM, et al. Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene 2008;27:2055–63.
   PubMed Web of Science ®Google Scholar